The Greater Cannabis Company, Inc. (OTCMKTS: GCAN) continues to trade strong in recent weeks. In April the Company announced a letter of agreement (LOI) with leading Brazilian beauty and personal care company Allume Cosmeticos. Under the terms of the agreement, Greater Cannabis Company will customize formulations and incorporate its proprietary technology to infuse pharmaceutical-grade cannabidiol (CBD) into Allume’s new line of CBD-based cosmetic products, empowering Allume to market and distribute CBD-infused beauty and personal care for its retail partners, distributors and millions of customers.
CBD has shown multiple beauty and personal care benefits, ranging from antioxidants for anti-aging to anti-inflammatory for acne and other treatments. Its effectiveness in these applications requires excellent product bioavailability and reliable stability. Greater Cannabis Company’s patented technology platform has demonstrated this in the delivery of cannabis actives across different mediums in lab studies, including beauty and personal care. The company combines this with expertise and innovation in concept development to full-scale commercialization to assist its retail and manufacturing clients in bringing CBD products to market.
The Greater Cannabis Company, Inc. (OTCMKTS: GCAN) bills itself as a biotechnology company focused on the development and commercialization of innovative Cannabinoid delivery systems. Greater Cannabis deploys its licensed, patented technology platform, which has been successfully applied for other drug delivery applications, for use in Cannabis patients and consumers. The company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other cannabinoid delivery methods. The technology is versatile in that for the first-time patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using a fully dissolvable, non-irritant oral eluting patch.
Greater Cannabis’ mission is to bring their technology to the global market through partnerships with leading Cannabis and pharmaceutical companies, for the benefit of patients and consumers. The Company’s business model is divided into four operating segments through their wholly owned subsidiaries; Bud Bank, Inc., GCC Superstore, LLC and GCC Investment Holdings, LLC: The Company is led by Aitan Zacharin, an executive who co-founded Fuse Science, an innovative biotechnology company headquartered in Miami, Florida and Oxnard, California.
In August GCAN acquired Green C Corporation through a Share Exchange Agreement. Green C is a Canadian company focused on innovative delivery systems for the Cannabis industry and has the exclusive worldwide license for PharMedica’s Eluting Transmucosal Patch Platform (ETP) for non-invasive drug delivery for use in the Cannabis field. The company holds the rights to new delivery technologies using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides for a needle free, intra-oral systemic drug delivery. The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and nutraceuticals when compared to traditional methods of enteral administration.
To Find out the inside Scoop on GCAN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
The Greater Cannabis Company appointed Aitan Zacharin as CEO. Mark Radom as chief legal officer, and corporate counsel. Mr. Zacharin is an experienced executive with a broad knowledge in building and managing technology and consumer products businesses. In 2012, he co-founded Fuse Science, an innovative biotechnology company headquartered in Miami, Florida and Oxnard, California. Mark Radom served as chief executive officer of Graphite Corp. From February 2010 through July 2015, Mr. Radom served as the chief carbon officer and general counsel of Blue Sphere Corporation. From 2009 through 2010, Mr. Radom was managing director of Carbon MPV Limited, a Cyprus company focused on developing renewable energy and carbon credit projects.
On May 1 GCAN announced it was featured in a live interview today at 1:10 pm EST on the Cheddar Financial News Network on the floor of the New York Stock Exchange (NYSE) during trading hours. During today’s segment, the Company’s Chairman and Chief Executive Officer, Aitan Zacharin, is expected to provide a brief summary of the history of Greater Cannabis Company, why and how it was formed and, in particular, its proprietary cannabinoid delivery system, which is anticipated to become one of the most disruptive technologies in cannabis industry since its legalization. Please note the interview can be viewed on the Cheddar.tv website and other services the network streams to., which can be found on its site. A recording of the interview will be available shortly after on the Company’s website.
Cannabis has been increasingly growing in validity and presence among the senior exchanges in the U.S., including NYSE and NASDAQ, as well as the traditional blue-chip investment banks such as the Bank of America, which announced that it will begin providing analyst coverage of the cannabis sector. Additionally, funding for U.S-based cannabis companies is continuing to break historical records.
We have a Monster Pick Coming. Subscribe Right Now!
GCAN has no cash in the treasury and fast rising debt with no reven ues to date. One cannot argue with the $1 million per day in dollar volume and huge gains that GCAN is currently making. The stock has quickly attracted a large shareholder base who notes the tight share structure and hopes the parabolic run continues. GCAN has been light on news so far. The Company has licensed a patented cannabinoid delivery system which has been successfully applied for other drug delivery applications. According to CEO Aitan Zacharin “We have licensed a technology that comes from decades of research and development of a novel delivery system, which improves drug bioavailability with improved efficacy. I look forward to working with our team in an effort to bring this important innovation to the global Cannabis market, and address a real unmet need for millions of patients.” GCAN recently said it is now DTC eligible. Existing shareholders now have the ability to electronically deposit their shares through the DWAC platform into their brokerage account. We will be updating on GCAN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GCAN.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in GCAN either long or short and we have not been compensated for this article.